Sysmex (OTCMKTS:SSMXY) Shares Gap Up – Should You Buy?

Sysmex Corporation ADR (OTCMKTS:SSMXY)’s share price gapped up prior to trading on Thursday . The stock had previously closed at $8.98, but opened at $9.48. Sysmex shares last traded at $9.46, with a volume of 1,767 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Citigroup downgraded Sysmex from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 16th. One investment analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold”.

Sysmex Stock Performance

The stock has a market cap of $5.93 billion, a PE ratio of 24.79 and a beta of 1.10. The firm’s 50-day moving average is $8.71 and its 200 day moving average is $9.09. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.46 and a current ratio of 3.26.

Sysmex (OTCMKTS:SSMXY) last issued its quarterly earnings data on Thursday, May 14th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.02). The business had revenue of $877.92 million for the quarter, compared to analysts’ expectations of $862.45 million. Sysmex had a return on equity of 7.23% and a net margin of 7.13%.Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. As a group, research analysts anticipate that Sysmex Corporation ADR will post 0.42 EPS for the current year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.